"Buffalo hump" associated with the use of indinavir.

Background. Since 1997, new side effects like lipodystrophia have been desc ribed in HIV-1-infected patients treated with protease inhibitors. The evol ution is not specified in the most reported cases. Case report. A 44-year-old man treated for HIV 1 infection developed a Buff alo hump 12 months after initiating a new treatment including indinavir-pro tease inhibitor (Crixivan(R)). Ten months later, we observe neither other f at accumulation nor fat loss and significant metabolic disorders. Discussion, Many publications emphasized the relationship that would exist between protease inhibitors therapy and the occurrence of lipodystrophia. C linical features of this syndrome appear like an accumulation of fatty tiss ue anywhere on the trunk, or a fat loss on the limbs, the buttocks and the face. It is sometimes associated with metabolic disorders. The pathogenesis of these lipodystrophia is unclear. Larger studies have to be led to high light the incidence of these lipodystrophia and their subsequent effects on the HIV-1 infection.